National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Tadalafil (Adcirca®) is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as World Health Organisation (WHO) Functional Class (FC) II and III, to improve exercise capacity.

Rapid Review

Commenced Completed Outcome
13/07/2011 21/09/2011 Full Pharmacoeconomic Evaluation not Recommended

 

May 2014

In accordance with the Health Act (Pricing and Supply of Medical Goods) 2013 (section 18(4)), the HSE has requested the NCPE to re-examine the cost effectiveness of Tadalafil (Adcirca®).

 

Rapid Review

Commenced Completed Outcome
09/05/2014 23/05/2014 Full Pharmacoeconomic Evaluation Not Recommended